Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06351371 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Mutations or Fusions (MATCH - Subprotocol K2)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 20 words
    • Secondary endpoints: details revised at 2 of 2 entries
  2. 26 versions Re-verified since Mar 7, 2026, no change to tracked fieldsv10-v35
  3. Study completion date: Dec 31, 2025 to Jan 15, 2027v9
  4. 2 versions Re-verified since Sep 2, 2025, no change to tracked fieldsv7-v8
  5. Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Erdafitinib (Drug), Magnetic Resonance Imaging… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Erdafitinib (Drug), Magnetic Resonance…v6
Show 4 earlier versionsHide 4 earlier versions
  1. Re-verified, no change to tracked fieldsv5
  2. Eligibility criteria shortened, about 2 wordsv4
  3. Results first posted: Jun 18, 2024v3
  4. Primary completion date changed from estimate of Jun 30, 2024 to Jun 2, 2022v2 Show 6 more changesShow less
    • Study completion date: Jun 30, 2024 to Dec 31, 2025
    • Start date: Jun 19, 2018 to Jul 3, 2018
    • Secondary endpoints: 3 to 2
    • Primary endpoint revised
    • Study description expanded, about 17 words
    • Eligibility criteria expanded, about 2 words
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II MATCH treatment trial tests how well erdafitinib (JNJ-42756493) works in treating patients with tumors that have FGFR mutations or fusions. Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals cancer cells to multiply. This may help keep cancer cells from growing and may kill them.
Trial Details
NCT Number NCT06351371
Lead Sponsor National Cancer Institute (NCI)
Conditions
(from sponsor)		 Malignant Solid Neoplasm
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov